Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
52 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pyelonephritis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pyelonephritis - Pipeline Review, H2 2014', provides an overview of the Pyelonephritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pyelonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pyelonephritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pyelonephritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pyelonephritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pyelonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pyelonephritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pyelonephritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pyelonephritis Overview 6 Therapeutics Development 7 Pipeline Products for Pyelonephritis - Overview 7 Pipeline Products for Pyelonephritis - Comparative Analysis 8 Pyelonephritis - Therapeutics under Development by Companies 9 Pyelonephritis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Pyelonephritis - Products under Development by Companies 12 Pyelonephritis - Companies Involved in Therapeutics Development 13 Achaogen Inc. 13 AstraZeneca PLC 14 Cubist Pharmaceuticals, Inc. 15 Merck & Co., Inc. 16 MerLion Pharmaceuticals Pte Ltd 17 The Medicines Company 18 Pyelonephritis - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 (ceftazidime + avibactam) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 (ceftolozane + tazobactam) - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 (RPX-2014 + RPX-7009) - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 finafloxacin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 plazomicin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 relebactam - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Pyelonephritis - Recent Pipeline Updates 40 Pyelonephritis - Dormant Projects 48 Pyelonephritis - Discontinued Products 49 Pyelonephritis - Product Development Milestones 50 Featured News & Press Releases 50 May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 50 May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables Number of Products under Development for Pyelonephritis, H2 2014 7 Number of Products under Development for Pyelonephritis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Pyelonephritis - Pipeline by Achaogen Inc., H2 2014 13 Pyelonephritis - Pipeline by AstraZeneca PLC, H2 2014 14 Pyelonephritis - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 15 Pyelonephritis - Pipeline by Merck & Co., Inc., H2 2014 16 Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2014 17 Pyelonephritis - Pipeline by The Medicines Company, H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Assessment by Combination Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 27 Pyelonephritis Therapeutics - Recent Pipeline Updates, H2 2014 40 Pyelonephritis - Dormant Projects, H2 2014 48 Pyelonephritis - Discontinued Products, H2 2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.